Reducing the time and expense of engineering PROTAC degraders remains a significant challenge in the pharmaceutical industry. A PROTAC is composed of an E3 ligase ligand (E3-L), a protein of interest ...
The "Global PROTAC Targeted Protein Degraders Market Opportunity & Clinical Trials Insight 2027" report has been added to ResearchAndMarkets.com's offering. First conceptualized in the early 2000s, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback